StockWatch
·

LINCOLN PHARMACEUTICALS LTD. Q3 FY25 Results

LINCOLNQ3 FY25 Results
Filing
MetricValue ( Cr)vs Q2 FY25
Revenue146.559.1%
Total Income155.529.2%
Expenditure126.847.0%
PBT28.6817.5%
Net Profit20.7721.1%
OPM10.75%2.42pp
NPM13.35%2.03pp
EPS10.3721.1%
View full financials

Informational and educational content only. Not investment advice.